Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2510924 with Idarubicin and Cytarabine in Relapsed/Refractory AML
NCT02652871Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2016
- Primary completion
- Jul 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LY2510924 in acute myeloid leukemia (AML), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Dose Limiting Toxicity at 30 days. Started May 2016; status: completed.
02
Drugs
LY2510924
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02652871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02652871.